Clinical trials: Non-Proliferative Diabetic Retinopathy
Non Proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy
Changes in Electroretinogram and Contrast Sensitivity After PASCAL Treatment
Laser photocoagulation has become the treatment of choice in PDR. Laser photocoagulation has become the treatment of choice in PDR.
- Trial name
- NCT00563043
- Testing
- PASCAL laser treatment
- Where
- Mexico
- Volunteers
- 8 people
- Sponsor
- Asociación para Evitar la Ceguera en México
Mild Non-proliferative Diabetic Retinopathy, Cataract Diabetic
Phacoemulsification Combined With Intravitreal Injection of Ranibizumab Prevent Postoperative Capillary Non-perfusion Zone Progress in Non-proliferative Diabetic Retinopathy
Diabetic retinopathy has been found progress in 20-70% diabetic patient after cataract phacoemulsification surgery. Intravitreal injection of anti-VEGF Ranibizumab is an important treatment for diabetic retinopathy including…
- Conditions
- Mild Non-proliferative Diabetic Retinopathy, Cataract Diabetic, Diabetic Retinopathy
- Trial name
- NCT05386160
- Testing
- Ranibizumab Injection [Lucentis], Phacoemulsification
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Ruijin Hospital
Diabetic Retinopathy
Study to Evaluate Clinical Efficacy and Safety of Nuvastatic™ - C5OSEW5050ESA in Diabetic Retinopathy.
Diabetic retinopathy (DR) is a common complication of diabetes mellitus that leads to loss of vision and blindness among working age adults.
- Trial name
- NCT04552600
- Testing
- Nuvastatic
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Natureceuticals Sdn Bhd
NPDR - Non Proliferative Diabetic Retinopathy, Diabetes Mellitus, Type 2
Characterization of Retinal Disease Progression in Eyes With Non Proliferative Diabetic Retinopathy in Diabetes Type 2 Using Non-invasive Procedures (CHART)
To identify biomarkers, obtained using non-invasive procedures, that can predict disease progression and progression to sight-threatening stages of the disease and to characterize the retinal changes that occur in Non…
- Conditions
- NPDR - Non Proliferative Diabetic Retinopathy, Diabetes Mellitus, Type 2, Retinal Disease
- Trial name
- CHART (NCT04636307)
- Testing
- Biomarkers
- Where
- 5 sites in France, Italy and 1 more
- Volunteers
- 202 people
- Sponsor
- Association for Innovation and Biomedical Research on Light and Image
Diabetic Retinopathy
Trientine Hydrochloride for the Prevention of Macular Edema Associated With Pan-retinal Photocoagulation for Severe Non-proliferative and Proliferative Diabetic Retinopathy
To evaluate the effects of Trientine Hydrochloride in prevention of post-laser (pan-retinal photocoagulation) macular edema in the eyes for subjects with diabetic retinopathy.
- Trial name
- NCT01213888
- Testing
- Trientine Hydrochloride
- Where
- Canada
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG)
Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation
Pilot, single-site, prospective study of QLS-111 0.015 % in subjects with NPDR, OAG or NTG
- Conditions
- Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG), Normal Tension Glaucoma (NTG)
- Trial name
- (PENGUIN) (NCT07354477)
- Testing
- QLS-111 Ophthalmic Solution (0.015%), QLS-111 Ophthalmic Solution (0.075%)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Qlaris Bio, Inc.
Diabetic Retinopathy, Sleep Apnea
CPAP Effect on the Progression of Diabetic Retinopathy in Patients With Sleep Apnea
Objectives: Main objective: To compare the percentage of patients with new microaneurysm or hard exudates after 12 months between the CPAP group and the control group.
- Trial name
- RetinAS (NCT02874313)
- Testing
- Continuous positive airway pressure, Pharmacological treatment, Conventional anti-diabetic diet recommendations
- Where
- Spain
- Volunteers
- 82 people
- Sponsor
- Hospital Universitario La Paz
Diabetic Retinopathy, Non-Proliferative Diabetic Retinopathy
Remote Ischemic Conditioning for Non-Proliferative Diabetic Retinopathy
The goal of this clinical trial is to evaluate whether remote ischemic conditioning (RIC) is a safe and effective treatment for non-proliferative diabetic retinopathy (NPDR) in adults aged 40-80 years with type 2 diabetes.
- Conditions
- Diabetic Retinopathy, Non-Proliferative Diabetic Retinopathy, Remote Ischemic Conditioning, Diabetes Mellitus, Type 2
- Trial name
- RIC-NPDR (NCT06713720)
- Testing
- Remote Ischemic Conditioning Device
- Where
- 2 sites in China
- Volunteers
- 68 people
- Sponsor
- Xuxiang Zhang, MD
Diabetic Retinopathy
Evaluation of Doxycycline Verses Placebo for the Treatment of Severe Nonproliferative or Mild or Moderate Proliferative Diabetic Retinopathy
This 24 month randomized research study will evaluate whether doxycycline can 1) slow the deterioration or improve retinal function and/or 2) induce regression, or slow progression, of diabetic retinopathy in participants over 18…
- Trial name
- POC1 (NCT00511875)
- Testing
- doxycycline monohydrate
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Thomas Gardner
Retinopathy, Diabetic
Evaluation of the Retina in Patients With Non-proliferative Diabetic Retinopathy After Aflibercept Injection in the Eye
The purpose of this study is to specifically assess the effect of intravitreal aflibercept injections on the health of cells and the flow of blood through the retinal blood vessels by using advanced technology called adaptive…
- Trial name
- PRAVA (NCT04702048)
- Testing
- Aflibercept Injection
- Where
- United States
- Sponsor
- University of Rochester
Type 2 Diabetes Mellitus, Mild Nonproliferative Diabetic Retinopathy
Biomarkers of Diabetic Retinopathy Progression
The purpose of this study is to validate a predictive model of diabetic retinopathy progression in patients with diabetes mellitus type 2 patients to clinically significant macular edema (CSME) needing treatment either…
- Trial name
- C-Tracer (NCT01607190)
- Where
- 2 sites in India, Portugal
- Volunteers
- 200 people
- Sponsor
- Association for Innovation and Biomedical Research on Light and Image
Diabetic Retinopathy
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy
This study is open to adults with diabetic retinopathy. People who have non-proliferative diabetic retinopathy of moderate or high severity can join the study.
- Trial name
- NCT06321302
- Testing
- BI 764524, Aflibercept (Eylea®) - US only
- Where
- 90 sites in United States, Germany and 7 more
- Volunteers
- 175 people
- Sponsor
- Boehringer Ingelheim
Mild Nonproliferative Diabetic Retinopathy, Moderate Nonproliferative Diabetic Retinopathy
Diabetic Macular Edema and Diabetic Retinopathy Screening (TeleMed) With Automated Retinal Photography
The purpose of this study is explore if a partnership and screening program put in place between a busy retina practice and their referring diabetes care offices can improve diabetic retinopathy and diabetic macular edema…
- Conditions
- Mild Nonproliferative Diabetic Retinopathy, Moderate Nonproliferative Diabetic Retinopathy, Severe Nonproliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy
- Trial name
- DIVER (NCT01790945)
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Retina Institute of Hawaii
Central Retinal Vein Occlusion, Proliferative Diabetic Retinopathy
Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion
The purpose of this study is to look at how effective, safe, and well tolerated Intravitreal Aflibercept Injection is in subjects with Central Retinal Vein Occlusion (CRVO) or Proliferative Diabetic Retinopathy (PDR).
- Trial name
- ANDROID (NCT01724554)
- Testing
- Intravitreal Aflibercept Injection
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Ophthalmic Consultants of Boston
Diabetic Retinopathy
Validation of a Predictive Model to Estimate the Risk of Conversion to Clinically Significant Macular Edema and/or Vision Loss in Mild Nonproliferative Diabetic Retinopathy in Diabetes Type 2
This project aims to validate a predictive model of diabetic retinopathy progression to clinically significant macular edema (CSME) needing photocoagulation and/or vision loss.
- Trial name
- CPM (NCT00763802)
- Where
- Portugal
- Volunteers
- 400 people
- Sponsor
- Association for Innovation and Biomedical Research on Light and Image
Proliferative Diabetic Retinopathy
Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy
The RECOVERY trial will assess the safety and tolerability of 2 mg intravitreal aflibercept injections (IAI) given monthly (Q4WK) or every 12 weeks (Q12WK) for the treatment of retinal capillary non-perfusion (RNP) associated…
- Trial name
- RECOVERY (NCT02863354)
- Testing
- Aflibercept
- Where
- 4 sites in United States
- Volunteers
- 43 people
- Sponsor
- Charles C Wykoff, PhD, MD
Non-Proliferative Diabetic Retinopathy
Safety and Efficacy of Faricimab in Patients With NPDR
The purpose of this Phase 2 study is comprised of two groups to evaluate the safety, tolerability, and efficacy of faricimab in patients with Non-Proliferative Diabetic Retinopathy.
- Trial name
- MAGIC (NCT05681884)
- Testing
- Faricimab
- Where
- 16 sites in United States
- Volunteers
- 179 people
- Sponsor
- Greater Houston Retina Research
NPDR - Non Proliferative Diabetic Retinopathy
Characterization of Retinal Vascular Disease in Eyes With Mild to Moderate NPDR in Diabetes Type 2
Characterization of Retinal vascular disease in eyes with mild to moderate NPDR in Diabetes type 2, using novel non-invasive Imaging methods, in a longitudinal, prospective and interventional clinical Study with 2 years of…
- Trial name
- CORDIS (NCT03696810)
- Testing
- Laboratory tests
- Where
- Portugal
- Volunteers
- 141 people
- Sponsor
- Association for Innovation and Biomedical Research on Light and Image
Diabetic Retinopathy
Lowering Events in Non-proliferative Retinopathy in Scotland
LENS is a streamlined multicentre randomised placebo-controlled parallel-group trial investigating the effect of fenofibrate treatment on the progression of diabetic retinopathy/maculopathy.
- Trial name
- LENS (NCT03439345)
- Testing
- Fenofibrate 145 mg
- Where
- 16 sites in United Kingdom
- Volunteers
- 1,151 people
- Sponsor
- University of Oxford
Non-Proliferative Diabetic Retinopathy, Cataract
Nepafenac Once Daily for Macular Edema - Study 1
The purpose of this study is to demonstrate superiority of Nepafenac Ophthalmic Suspension, 0.3% dosed once daily relative to Nepafenac Vehicle based upon clinical outcomes among diabetic subjects following cataract surgery.
- Trial name
- NCT01853072
- Testing
- Nepafenac Ophthalmic Suspension, 0.3%, Nepafenac vehicle, Prednisolone acetate
- Volunteers
- 881 people
- Sponsor
- Alcon Research